CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

Table 3 Univariate and pairwise multivariate Cox Proportional Hazards analysis for time-to-distant metastasis.

	Number of samples	Hazard Ratio (95% CI)	p-value^‡
Univariate Analysis ^†
CDO1 DNA Methylation	78	3.7 (1.4 - 9.8)	0.0098
Age at Surgery	78	1.3 (0.6 - 2.8)	0.5545
Tumor Stage (T2,T3 vs. T1)	78	2.0 (0.7 - 5.2)	0.1799
Progesterone Receptor Status (Positive vs. Negative)	77	2.7 (1.2 - 6.0)	0.0190
Endocrine Treatment (No vs. Yes)	77	2.0 (0.9 - 4.5)	0.1115
Tumor Grade (3 vs.1,2)	61	2.0 (0.8 - 4.9)	0.1397
Pairwise Multivariate Analysis ^†
CDO1 DNA Methylation	78	3.9 (1.5 - 10.5)	0.0072
Age at Surgery	78	1.5 (0.7 - 3.4)	0.3160
CDO1 DNA Methylation	77	3.5 (1.3 - 9.5)	0.0128
T Stage (T2,T3 vs. T1)	77	2.0 (0.7 - 5.3)	0.1790
CDO1 DNA Methylation	78	3.5 (1.3 - 9.4)	0.0123
Progesterone Receptor Status (Positive vs. Negative)	78	2.5 (1.1 - 5.7)	0.0275
CDO1 DNA Methylation	77	4.6 (1.6 - 13.5)	0.0055
Endocrine Treatment (No vs. Yes)	77	2.0 (0.9 - 4.7)	0.0938
CDO1 DNA Methylation	61	3.1 (1.1 - 8.7)	0.0318
Tumor Grade (3 vs.1,2)	61	1.7 (0.7 - 4.3)	0.2506

^†CDO1 DNA methylation and age at surgery were analyzed as continuous variables. T stage, endocrine treatment and progesterone receptor status were analyzed as binary variables.
^‡p-values refer to Likelihood-ratio test.

ISSN: 1471-2407